MaaT Pharma's MaaT034 Shows 83.7% Tumor Growth Reduction in Preclinical Studies at SITC 2025
核心洞察
MaaT Pharma (搜索) presented updated preclinical data for MaaT034 at SITC 2025, demonstrating 83.7% tumor growth reduction when combined with anti-PD1 (搜索) therapy compared to 10% reduction with anti-PD1 alone.
The first-in-class co-cultured microbiome therapy successfully engrafted 70% of microbial species in germ-free mice and enhanced dendritic cell-mediated T cell activation.
MaaT034 is designed to optimize intestinal microbiome functions and improve patient responses to immunotherapy using AI-driven co-culture technology for donor-independent synthetic microbiome ecosystems.
MaaT Pharma (搜索) announced compelling preclinical results for its next-generation microbiome therapy MaaT034 at the 40th Society for Immunotherapy Cancer (搜索) Annual Meeting in National Harbor, MD. The data demonstrates significant anti-tumor efficacy and immune activation in germ-free mouse models, positioning the therapy as a potential breakthrough in cancer immunotherapy enhancement.
Significant Tumor Growth Inhibition
The most striking finding showed that MaaT034 in combination with anti-PD1 (搜索) therapy achieved an 83.7% tumor growth reduction in tumor-bearing, germ-free mice. This represents a dramatic improvement over anti-PD1 monotherapy, which reduced tumor growth by only 10%. The combination therapy also significantly outperformed anti-PD1 combined with a single strain of Akkermansia muciniphila bacteria, which achieved only 24.2% tumor growth reduction.
Successful Microbial Engraftment and Metabolic Activity
Metagenomic analysis revealed that 70% of MaaT034 microbial species successfully engrafted in mice, ensuring an enduring presence of beneficial bacteria in the gut environment. According to the company, this level of engraftment is significantly associated with positive clinical outcomes across multiple indications in human fecal microbiota transplantation studies, as demonstrated by recent comprehensive meta-analysis.
The therapy increased production of key microbial-derived metabolites including short-chain fatty acids, secondary bile acids, and tryptophan metabolites in germ-free mice. This metabolic activity translated into improved gastrointestinal physiology, evidenced by gut mucosal restoration.
Enhanced Immune System Activation
MaaT034 demonstrated the ability to improve dendritic cell-mediated T cell activation and potentiate anti-tumor effects mediated by anti-PD-1 (搜索) checkpoint blockade in vitro. The therapy successfully reproduced the microbial functions of native-based microbiome ecosystems, supporting its role in gut barrier repair and T cell reactivation.
AI-Driven Technology Platform
MaaT034 represents the first-in-class co-cultured full ecosystem product developed using the company's proprietary MET-C platform. This technology leverages artificial intelligence-driven co-culture methods to create donor-independent synthetic microbiome ecosystems at industrial scale, targeting specific disease indications.
"With MaaT034, we are entering a new phase in our drug platform development, one that leverages our deep experience in the development of complex microbiome therapies and cutting-edge computational analysis to build a next-generation drug candidate capable of enhancing patient response to immunotherapy," said Sheri Simmons, PhD, Acting Chief Scientific Officer at MaaT Pharma (搜索).
Clinical Development Pipeline
While MaaT034 remains in preclinical development, MaaT Pharma (搜索) is simultaneously advancing two exploratory, investigator-sponsored clinical trials evaluating donor-derived drug candidates. MaaT013 is being evaluated in metastatic melanoma (搜索), while MaaT033 is being tested in non-small cell lung cancer (搜索), both in combination with immune checkpoint inhibitors.
The company plans to advance MaaT034 into clinical development based on these compelling preclinical results. MaaT Pharma (搜索) will present additional data at upcoming conferences including the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire annual meeting in Geneva and the American Society of Hematology annual meeting in Orlando.